| Monika Komosinski, CRNA | |
|
703 Main St, Paterson, NJ 07503-2621 | |
| (973) 754-2000 | |
| Not Available |
| Full Name | Monika Komosinski |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 20 Years |
| Location | 703 Main St, Paterson, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306812276 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 26NR09472000 (New Jersey) | Primary |
| 367500000X | Nurse Anesthetist, Certified Registered | 26NJ00250100 (New Jersey) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Clara Maass Medical Center | Belleville, NJ | Hospital |
| Newton Medical Center | Newton, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Of Morristown Pa | 7315906591 | 132 |
| North American Partners In Anesthesia Of New Jersey Llc | 5890867410 | 226 |
| Parkway Anesthesia Associates Llc | 2567758931 | 126 |
News Archive
Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
Researchers at the University of Rochester Medical Center has announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk.
Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.
Young sexual minority men - including those who are gay, bisexual, queer or straight-identified men who have sex with men - do not fully understand their risk for human papillomavirus due to a lack of information from health care providers, according to Rutgers researchers.
› Verified 3 days ago
| Entity Name | Morris Anesthesia Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194728501 PECOS PAC ID: 4284628645 Enrollment ID: O20040409000402 |
News Archive
Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
Researchers at the University of Rochester Medical Center has announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk.
Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.
Young sexual minority men - including those who are gay, bisexual, queer or straight-identified men who have sex with men - do not fully understand their risk for human papillomavirus due to a lack of information from health care providers, according to Rutgers researchers.
› Verified 3 days ago
| Entity Name | Anesthesia Associates Of Morristown Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922057678 PECOS PAC ID: 7315906591 Enrollment ID: O20041004000993 |
News Archive
Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
Researchers at the University of Rochester Medical Center has announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk.
Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.
Young sexual minority men - including those who are gay, bisexual, queer or straight-identified men who have sex with men - do not fully understand their risk for human papillomavirus due to a lack of information from health care providers, according to Rutgers researchers.
› Verified 3 days ago
| Entity Name | North American Partners In Anesthesia Of New Jersey Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548433048 PECOS PAC ID: 5890867410 Enrollment ID: O20080626000318 |
News Archive
Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
Researchers at the University of Rochester Medical Center has announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk.
Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.
Young sexual minority men - including those who are gay, bisexual, queer or straight-identified men who have sex with men - do not fully understand their risk for human papillomavirus due to a lack of information from health care providers, according to Rutgers researchers.
› Verified 3 days ago
| Entity Name | Prime Healthcare Services - St Mary's Passaic, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730508250 PECOS PAC ID: 6305066911 Enrollment ID: O20141031000263 |
News Archive
Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
Researchers at the University of Rochester Medical Center has announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk.
Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.
Young sexual minority men - including those who are gay, bisexual, queer or straight-identified men who have sex with men - do not fully understand their risk for human papillomavirus due to a lack of information from health care providers, according to Rutgers researchers.
› Verified 3 days ago
| Entity Name | Parkway Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518319755 PECOS PAC ID: 2567758931 Enrollment ID: O20160912000258 |
News Archive
Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
Researchers at the University of Rochester Medical Center has announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk.
Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.
Young sexual minority men - including those who are gay, bisexual, queer or straight-identified men who have sex with men - do not fully understand their risk for human papillomavirus due to a lack of information from health care providers, according to Rutgers researchers.
› Verified 3 days ago
| Entity Name | Aztec Medical Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598392003 PECOS PAC ID: 2961820527 Enrollment ID: O20200914001418 |
News Archive
Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
Researchers at the University of Rochester Medical Center has announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk.
Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.
Young sexual minority men - including those who are gay, bisexual, queer or straight-identified men who have sex with men - do not fully understand their risk for human papillomavirus due to a lack of information from health care providers, according to Rutgers researchers.
› Verified 3 days ago
| Entity Name | Capital Anesthesia Solutions Of New Jersey, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851908297 PECOS PAC ID: 1355761974 Enrollment ID: O20201021001347 |
News Archive
Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
Researchers at the University of Rochester Medical Center has announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk.
Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.
Young sexual minority men - including those who are gay, bisexual, queer or straight-identified men who have sex with men - do not fully understand their risk for human papillomavirus due to a lack of information from health care providers, according to Rutgers researchers.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Monika Komosinski, CRNA 3998 Fair Ridge Drive, Suite 300, Fairfax, VA 22033-2921 Ph: (703) 295-9360 | Monika Komosinski, CRNA 703 Main St, Paterson, NJ 07503-2621 Ph: (973) 754-2000 |
News Archive
Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
Researchers at the University of Rochester Medical Center has announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk.
Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.
Young sexual minority men - including those who are gay, bisexual, queer or straight-identified men who have sex with men - do not fully understand their risk for human papillomavirus due to a lack of information from health care providers, according to Rutgers researchers.
› Verified 3 days ago
Jeny Varughese, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-2000 | |
Ruthmarie Saunders, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 375 17th Ave, Paterson, NJ 07504 Phone: 718-828-2666 | |
Dr. Donna A Pearce, M.D. Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-2000 | |
Ms. Sharon Cecelia Barrett, APRN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 81 E 39th St, Paterson, NJ 07514 Phone: 973-600-9959 Fax: 201-488-0925 | |
Edward Michael Collins, APN Registered Nurse Medicare: Medicare Enrolled Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-2240 | |
Ryan James Murphy, RN, MSN, NP Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-2842 | |
Bobbi-jean Plummer, RN, APN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-3428 |